Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose versus toxicity-adjusted cisplatin + etoposide in advanced small cell lung cancer
2006-003995-36Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2007
- Modality
- Small Molecules, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, etoposide and darbepoetin alfa in small cell lung cancer (SCLC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Objective response. Started Jun 2007; status: completed.
02
Drugs
cisplatinetoposidedarbepoetin alfa
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2006-003995-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003995-36.